Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 14/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538904 | 1.00 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4HCAR2 | |
| SCHEMBL3538352 | 0.81 | CYP2C9 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3538355 | 0.81 | CYP2C9 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL31125777 | 0.80 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4HCAR2 | |
| SCHEMBL1843614 | 0.79 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3537744 | 0.79 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3537741 | 0.79 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29420013 | 0.77 | CHRNB2 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4HCAR2 | |
| SCHEMBL20187819 | 0.77 | CHRNB2 (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4HCAR2 | |
| SCHEMBL1665710 | 0.76 | USP2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| EP-2013178-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| WO-2007113202-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238737-A1 | NOVEL COMPOUNDS | FABP2, VIP, SLC10A2 | CHRNB4 2397/4885CHRNA3 2876/4885CHRNB2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.